FDA WARNING_LETTER - Plantacea, LLC dba Kahm - May 26, 2022

View on Dashboard

Discuss this record with AI

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Plantacea, LLC dba Kahm

Record Details

On May 26, 2022, the FDA issued a Warning Letter to Casey Bales and Brian Frye of Kahm CBD, following a review of their websites and social media in May 2022. The FDA determined that Kahm CBD was illegally marketing unapproved new human and animal drugs, misbranded drugs, and adulterated food products containing cannabidiol (CBD).

Specifically, "CBD Hemp Pellets" and "K9 Soft Chews" were cited as unapproved new animal drugs, unsafe under 21 U.S.C. 360b(a), and adulterated under 21 U.S.C. 351(a)(5). The FDA expressed particular concern about CBD products for food-producing animals due to potential residues in human food.

Human CBD products, including "Kahm EQUIPASS RELIEF GEL," "Kahm CBD MUSCLE FREEZE ROLL ON," "Kahm BODY CREAM," "Kahm CBD BROAD SPECTRUM HEMP EXTRACT," "Kahm CBD NANO CBD SALVE," "Tanka 30 day CBD Band," "Tanka T-FLEX Band," and "Tanka Collagen Band," were deemed unapproved new drugs sold in violation of 21 U.S.C. 355(a) and 331(d), and misbranded under 21 U.S.C. 35

Company: Plantacea, LLC dba Kahm
Inspection Date: May 26, 2022
Product Type: Veterinary
Office: Center for Veterinary Medicine
People: Ann M. Oxenham (Director)
Neal Bataller (Division Director)
Donald D. Ashley (Director)

Open in Dashboard

ID · a6387ada-8a2b-40f8-87e1-d1a2fe786915

Violation Codes10

21 U.S.C. 360b(a)21 U.S.C. 351(a)(5)21.U.S.C. 355(a)21 U.S.C. 331(d)21 U.S.C. 352(f)(1)21 U.S.C. 342(a)(2)(C)(i)21 U.S.C. 331(ll)21 U.S.C. 321(g)(1)21 U.S.C. 321(v)21 U.S.C. 332(a)

Full citation text and observation details available on the Dashboard.